DDInter298 DDInter1578
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends on an RNA-dependent RNA polymerase (RdRp) enzyme complex for genomic replication, which can be inhibited by a class of drugs known as nucleoside analogues. Remdesivir (GS-5734) is an adenosine triphosphate analogue first described in the literature in 2016 as a potential treatment for Ebola.[A191379, A222393] Broad antiviral activity of remdesivir is suggested by its mechanism of action, and to date, it has demonstrated _in vitro_ activity against the _Arenaviridae_, _Flaviviridae_, _Filoviridae_, _Paramyxoviridae_, _Pneumoviridae_, and _Coronaviridae_ viral families. Remdesivir activity against the _Coronaviridae_ family was first demonstrated in 2017, leading to considerable interest in remdesivir as a possible treatment for COVID-19.[A191427, A198810] Remdesivir was confirmed as a non-obligate chain terminator of RdRp from SARS-CoV-2 and the related SARS-CoV and MERS-CoV, and has been investigated in multiple COVID-19 clinical trials.[L12174, L12177] After initially being granted an FDA Emergency Use Authorization (EUA) on May 1st, 2020, remdesivir was fully approved by the FDA for the treatment of COVID-19 on October 22, 2020. Remdesivir is currently marketed under the trademark name VEKLURY by Gilead Sciences Inc. Remdesivir was also approved by the European Commission on July 3, 2020. Remdesivir in combination with [baricitinib] for the treatment of COVID-19, was granted an FDA Emergency Use Authorization on November 19, 2020.
Carboplatin {u} (Compound) treats {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is treated by {v} (Compound) Cisplatin
Cisplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Carboplatin {u} (Compound) binds {v} (Gene) GSTM1
GSTM1 {u} (Gene) is bound by {v} (Compound) Cisplatin
Cisplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Carboplatin {u} (Compound) binds {v} (Gene) SLC31A2
SLC31A2 {u} (Gene) is upregulated by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Carboplatin {u} (Compound) binds {v} (Gene) SLC31A1
SLC31A1 {u} (Gene) is downregulated by {v} (Compound) Terbinafine
Terbinafine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Carboplatin {u} (Compound) binds {v} (Gene) SLC31A1
SLC31A1 {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Carboplatin {u} (Compound) is included by {v} (Pharmacologic Class) Platinum-containing Compounds
Platinum-containing Compounds {u} (Pharmacologic Class) includes {v} (Compound) Oxaliplatin
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Carboplatin {u} (Compound) causes {v} (Side Effect) Venous thrombosis
Venous thrombosis {u} (Side Effect) is caused by {v} (Compound) Gentamicin
Gentamicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Carboplatin {u} (Compound) causes {v} (Side Effect) Pain
Pain {u} (Side Effect) is caused by {v} (Compound) Hydroxychloroquine
Hydroxychloroquine {u} may lead to a major life threatening interaction when taken with {v} Remdesivir
Carboplatin (Compound) treats esophageal cancer (Disease) and esophageal cancer (Disease) is treated by Cisplatin (Compound) and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Carboplatin (Compound) binds GSTM1 (Gene) and GSTM1 (Gene) is bound by Cisplatin (Compound) and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Carboplatin (Compound) binds SLC31A2 (Gene) and SLC31A2 (Gene) is upregulated by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Carboplatin (Compound) binds SLC31A1 (Gene) and SLC31A1 (Gene) is downregulated by Terbinafine (Compound) and Terbinafine may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Carboplatin (Compound) binds SLC31A1 (Gene) and SLC31A1 (Gene) is bound by Bortezomib (Compound) and SLC31A1 (Gene) is upregulated by Bortezomib (Compound) and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Carboplatin (Compound) is included by Platinum-containing Compounds (Pharmacologic Class) and Platinum-containing Compounds (Pharmacologic Class) includes Oxaliplatin (Compound) and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Carboplatin (Compound) causes Venous thrombosis (Side Effect) and Venous thrombosis (Side Effect) is caused by Gentamicin (Compound) and Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Carboplatin (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Hydroxychloroquine (Compound) and Hydroxychloroquine may lead to a major life threatening interaction when taken with Remdesivir